{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:37:45Z","timestamp":1792075065598,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T00:00:00Z","timestamp":1650153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jiph.2022.04.007","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T21:44:19Z","timestamp":1650491059000},"page":"589-593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Vancomycin Therapeutic Drug Monitoring (TDM) and Its Association with Clinical Outcomes: A Retrospective Cohort"],"prefix":"10.1016","volume":"15","author":[{"given":"Juhaina Salim","family":"Al-Maqbali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Al","family":"Shukri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawf Al","family":"Sabahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intisar","family":"AL-Riyami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah M.","family":"Al Alawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jiph.2022.04.007_bib1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-017-0764-7","article-title":"The whole price of vancomycin: toxicities, troughs, and time","volume":"77","author":"Jeffres","year":"2017","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jiph.2022.04.007_bib2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jiph.2022.04.007_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2022.04.007_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"10.1016\/j.jiph.2022.04.007_bib5","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3855\/jidc.9800","article-title":"Prospective evaluation of vancomycin therapeutic usage and trough levels monitoring","volume":"12","author":"Kabbara","year":"2018","journal-title":"J Infect Dev Ctries"},{"issue":"1","key":"10.1016\/j.jiph.2022.04.007_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jiph.2022.04.007_bib7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/phar.2376","volume":"40","author":"Rybak","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.jiph.2022.04.007_bib8","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/AAC.03147-14","article-title":"Optimizing the clinical use of vancomycin","volume":"60","author":"\u00c1lvarez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jiph.2022.04.007_bib9","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1592\/phco.29.11.1275","article-title":"Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists","volume":"29","author":"Rybak","year":"2009","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.jiph.2022.04.007_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077169","article-title":"Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis","volume":"8","author":"Ye","year":"2013","journal-title":"PLOS One"},{"issue":"5","key":"10.1016\/j.jiph.2022.04.007_bib11","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s13318-019-00551-1","article-title":"Clinical and pharmacokinetic outcomes of peak-trough-based versus trough-based vancomycin therapeutic drug monitoring approaches: a pragmatic randomized controlled trial","volume":"44","author":"Al-Sulaiti","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"7\u20138","key":"10.1016\/j.jiph.2022.04.007_bib12","doi-asserted-by":"crossref","first-page":"717","DOI":"10.36290\/vnl.2018.098","article-title":"The Scottish model of vancomycin dosing and therapeutic drug monitoring improves both efficacy and safety of vancomycin therapy","volume":"64","author":"Zah\u00e1lkov\u00e1","year":"2018","journal-title":"Vnitr Lek"},{"issue":"4","key":"10.1016\/j.jiph.2022.04.007_bib13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jiph.2022.04.007_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/j.1875-9114.1995.tb04335.x","article-title":"Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia","volume":"15","author":"Zimmermann","year":"1995","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.jiph.2022.04.007_bib15","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.amjmed.2010.07.025","article-title":"Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity","volume":"123","author":"Pritchard","year":"2010","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.jiph.2022.04.007_bib16","first-page":"498","article-title":"High sensitivity versus low level of vancomycin needs to be concern for another alternative anti- Staphylococcus aureus as the first- line antibiotic","volume":"90","author":"Talaie","year":"2019","journal-title":"Acta Biomed"},{"issue":"6","key":"10.1016\/j.jiph.2022.04.007_bib17","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.jiph.2022.04.007_bib18","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"issue":"3","key":"10.1016\/j.jiph.2022.04.007_bib19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/j.1875-9114.2011.01017.x","article-title":"Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort","volume":"32","author":"Kullar","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.jiph.2022.04.007_bib20","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00228-012-1259-9","article-title":"Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review","volume":"68","author":"Elyasi","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jiph.2022.04.007_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40121-019-00278-1","article-title":"A multicenter evaluation of vancomycin-associated acute kidney injury in hospitalized patients with acute bacterial skin and skin structure infections","volume":"9","author":"Jorgensen","year":"2020","journal-title":"Infect Dis Ther"},{"issue":"4","key":"10.1016\/j.jiph.2022.04.007_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1179\/1973947814Y.0000000182","article-title":"High versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis","volume":"27","author":"Meng","year":"2015","journal-title":"J Chemother"},{"issue":"7","key":"10.1016\/j.jiph.2022.04.007_bib23","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cmi.2015.04.003","article-title":"Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis","volume":"21","author":"Steinmetz","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.jiph.2022.04.007_bib24","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1053\/j.ajkd.2005.09.006","article-title":"Uncomplicated acute renal failure and hospital resource utilization: a retrospective multicenter analysis","volume":"46","author":"Fischer","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1016\/j.jiph.2022.04.007_bib25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1440-1797.2011.01488.x","article-title":"Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"16","author":"Shen","year":"2011","journal-title":"Nephrology"},{"issue":"1","key":"10.1016\/j.jiph.2022.04.007_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mayocp.2018.08.034","article-title":"Elevated vancomycin trough levels in a tertiary health system: frequency, risk factors, and prognosis","volume":"94","author":"Zonozi","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.jiph.2022.04.007_bib27","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.1128\/AAC.00168-11","article-title":"Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial","volume":"55","author":"Bosso","year":"2011","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034122000910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034122000910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:13:14Z","timestamp":1761750794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034122000910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1876034122000910"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2022.04.007","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vancomycin Therapeutic Drug Monitoring (TDM) and Its Association with Clinical Outcomes: A Retrospective Cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2022.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}